Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months.
Pediatr Blood Cancer
; 68(5): e28977, 2021 05.
Article
em En
| MEDLINE
| ID: mdl-33629819
ABSTRACT
Inhibition of platelet activation may reduce vaso-occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR-C124910XX) exposure were comparable across all groups (<6 months, ≥6 to <12 months and ≥12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Agregação Plaquetária
/
Ticagrelor
/
Anemia Falciforme
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article